Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) General Counsel Iqbal J. Hussain sold 6,000 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $16.45, for a total value of $98,700.00. Following the completion of the transaction, the general counsel now directly owns 105,386 shares in the company, valued at approximately $1,733,599.70. This represents a 5.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Centessa Pharmaceuticals Trading Up 1.6 %
CNTA stock opened at $16.77 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The company has a market capitalization of $2.21 billion, a price-to-earnings ratio of -10.96 and a beta of 1.54. The business has a 50 day simple moving average of $16.46 and a two-hundred day simple moving average of $16.36. Centessa Pharmaceuticals plc has a 1-year low of $7.75 and a 1-year high of $19.09.
Wall Street Analyst Weigh In
Several research analysts have recently commented on the company. TD Cowen assumed coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating on the stock. Morgan Stanley restated an "overweight" rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Finally, Guggenheim reiterated a "buy" rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $26.00.
Get Our Latest Research Report on Centessa Pharmaceuticals
Institutional Investors Weigh In On Centessa Pharmaceuticals
Large investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new position in Centessa Pharmaceuticals during the fourth quarter valued at approximately $31,000. GAMMA Investing LLC raised its holdings in shares of Centessa Pharmaceuticals by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after acquiring an additional 865 shares in the last quarter. Barclays PLC grew its holdings in shares of Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after purchasing an additional 4,952 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at $162,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in Centessa Pharmaceuticals in the fourth quarter worth $171,000. 82.01% of the stock is owned by institutional investors.
Centessa Pharmaceuticals Company Profile
(
Get Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
